Present and future vision of gene therapy: 360º approach
C/ Arzobispo Morcillo, 4
The Autonomous University of Madrid (UAM), in collaboration with the Esteve Foundation, the Spanish Society for Gene and Cell Therapy, the Instituto Fundación Teófilo Hernando and the Cell Therapy Network, organises a symposium with the aim of bringing together different gene therapy approaches and strategies and sharing the perspectives of the key actors in their development. The day, which will take place on 8 October 2018 at the Autonomous University of Madrid's School of Medicine , seeks to give the general public a glimpse into the fascinating field of gene therapy and how scientific progress can and does contribute to the well-being of humans.
WHY THIS SYMPOSIUM?
Over the last ten years, many steps have been taken that represent genuine progress in gene therapy. As a result, today a range of strategies exist to fight diseases that would be difficult to treat using other conventional approaches.This includes advances in the manipulation and production of viral vectors, progress in managing regulatory requirements and recognition of institutions, scientists and the general public. The event will provide a relaxed and intimate glimpse into the work of specialists in the field, essential for bringing the advances and challenges of this interesting therapeutic alternative to society as a whole.
Autonomous University of Madrid School of Medicine
C/ Arzobispo Morcillo 4
Monday, 8 October 2018
The Esteve Foundation
Spanish Society for Gene and Cell Therapy
Autonomous University of Madrid
Instituto Fundación Teófilo Hernando
Cell Therapy Network
Sociedad de Científicos Retornados a España (Society of Returned Researchers to Spain)
COORDINATORS: Dr. Silvia Gómez-Sebastián (UAM-CSIC); Dr. Jose Carlos Segovia (CIEMAT) and Dr. Enrique Tabarés (UAM)
Dr. Silvia Gómez-Sebastián, Dr. Jose Carlos Segovia and Dr. Enrique Tabarés (organisers). Felix Bosch (Director, Esteve Foundation), Dr. Gloria González Aseguinolaza (President-elect SETGyC).
Opening session:General aspects of gene therapy and safety with integrative vectors
Dr. Juan Güenechea (CIEMAT/CIBERER/IIS-FJD)
EX VIVO GENE THERAPY
Lentiviral gene therapy for pyruvate kinase deficiency:a step away from clinical application
Dr. Jose Carlos Segovia (CIEMAT)
Tuning of T lymphocytes with chimeric receptors to fight cancer: CAR-T cells
Dr. Juan Jose Lasarte (CIMA)
New gene therapy strategies for genetic skin diseases:Epidermolysis bullusa
Dr. Fernando Larcher (CIEMAT)
IN VIVO GENETIC THERAPY
Adeno-associated virus:the starting point for in vivo gene therapy for the treatment of hereditary diseases
Dr. Gloria G. Aseguinolaza (CIMA)
Viruses as anti-tumour agents:adeno-virus example
Dr. Ramón Alemany (ICO-IDIBELL)
Viruses as anti-tumour agents:herpes virus example
Dr. Silvia Gómez-Sebastián (UAM y CSIC)
RELEVANCE OF INFRASTRUCTURES IN GENE THERAPY
Title to be confirmed
Representative of the Spanish Agency of Medicines
Manufacturing viral vectors for gene therapy:current difficulties and challenges
Dr. Juan C. Ramírez (VIVEbioTECH)
GMP Rooms:Requirements for the manufacturing of advanced therapy drugs
Dr. Rosa Yañez (CIEMAT)
Role of clinical units in the development of gene therapy in monogenic diseases: from basic research to public health
Dr. Julián Sevilla (Hospital Niños Jesús)
Closing session:Advanced gene therapies with CRISPR genome editing tools:Current situation and outlook
Dr. Lluis Montoliu (CNB-CSIC y CIBERER-ISCIII)
This is a free event with limited seating. To attend, all you have to do is send an email to email@example.com with your name, surname, personal ID number, phone number and email address.
Online reservations are not available for this event.